Skip to content

Xencor XNCR Total debt

Total debt at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$21.57M-4.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$140.18M+107%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$7.49M-13.6%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Plus components not separately reported this period.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's total debt?
Xencor (XNCR) reported total debt of $175.16M in Q1 2026.
How has Xencor's total debt changed year-over-year?
Xencor's total debt decreased by 21.2% year-over-year, from $222.2M to $175.16M.
What is the long-term trend for Xencor's total debt?
Over 5 years (2020 to 2025), Xencor's total debt has grown at a 74.4% compound annual growth rate (CAGR), from $11.63M to $187.75M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.